Selective estrogen receptor modulators (SERMs) are increasingly used in the settings of breast cancer, osteoporosis, and postmenopausal symptoms [57], whereas and selective androgen receptor modulators (SARMs) have positive clinical potential for treatment of cancer-related cachexia, benign prostatic hyperplasia, hypogonadism, and breast cancer [58]. The gene discussed is ESR1; the disease is breast carcinoma.